We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
How much are pharma companies willing to pay in exchange for a faster trip to market in the U.K.? As it turns out, a cap of 2% on total branded-drug sales growth should do. And that’s a deal the industry is billing as a big savings for the government next